PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26100465-9 2015 We propose that e-cig users (vapers) achieve measurable serum nicotine levels when they inhale nicotine and nicotyrine together, because nicotyrine reversibly inhibits nicotine metabolism by CYP2A13 in airways. Nicotine 62-70 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 191-198 33215946-8 2021 CYP2E1 and CYP2A enzymes may contribute to the oxidative stress in the lungs caused by ethanol- and nicotine-metabolism, respectively. Nicotine 100-108 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 11-16 33055223-12 2020 This regulation by smoking/nicotine will increase interindividual variation in lung CYP2A levels that may impact the localized metabolism of inhaled drugs and tobacco smoke procarcinogens. Nicotine 27-35 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 84-89 33055223-15 2020 Lung CYP2A protein expression was decreased by systemic treatment with nicotine. Nicotine 71-79 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 5-10 29027939-0 2017 Nicotine Component of Cigarette Smoke Extract (CSE) Decreases the Cytotoxicity of CSE in BEAS-2B Cells Stably Expressing Human Cytochrome P450 2A13. Nicotine 0-8 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 127-147 29027939-2 2017 We previously found that nicotine inhibited 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism by CYP2A13, but its influence on other components of cigarette smoke remains unclear. Nicotine 25-33 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 111-118 29027939-10 2017 These results demonstrate that the nicotine component decreases the metabolic activation of CYP2A13 to CSE and aids in understanding the critical role of CYP2A13 in human respiratory diseases caused by cigarette smoking. Nicotine 35-43 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 92-99 29027939-10 2017 These results demonstrate that the nicotine component decreases the metabolic activation of CYP2A13 to CSE and aids in understanding the critical role of CYP2A13 in human respiratory diseases caused by cigarette smoking. Nicotine 35-43 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 154-161 34165800-3 2021 Candidate gene studies of smoking phenotypes have identified several pharmacogenes implicated in nicotine"s pharmacokinetics (CYP2A6, CYP2B6, CYP2A13, FMOs, UGTs, and OCT2), and nicotine"s pharmacodynamic response in the central nervous system (nicotinic acetylcholine receptors, as well as through the dopaminergic and serotonergic systems). Nicotine 97-105 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 142-149 33055223-0 2020 The influence of tobacco smoke/nicotine on CYP2A expression in Human and African Green Monkey Lungs. Nicotine 31-39 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 43-48 33055223-1 2020 CYP2A enzymes metabolically inactivate nicotine and activate tobacco-derived procarcinogens (e.g. NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone). Nicotine 39-47 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 0-5 33055223-2 2020 Smoking decreases nicotine clearance, and chronic nicotine reduces hepatic CYP2A activity. Nicotine 50-58 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 75-80 33055223-3 2020 However, little is known about the impact of smoking or nicotine on the expression of CYP2A in the lung. Nicotine 56-64 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 86-91 33055223-4 2020 We investigated 1) the levels of human lung CYP2A mRNA in smokers versus non-smokers and 2) the impact of daily nicotine treatment on lung CYP2A protein levels in African Green Monkeys (AGM). Nicotine 112-120 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 139-144 33055223-6 2020 The impact of chronic twice daily subcutaneous nicotine at two doses (0.3 and 0.5 mg/kg), versus vehicle, on lung CYP2A protein levels was assessed. Nicotine 47-55 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 114-119 33055223-9 2020 Both doses of nicotine tested decreased AGM lung CYP2A protein (3 to 7-fold). Nicotine 14-22 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 49-54 29342418-0 2018 Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation. Nicotine 75-83 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 33-40 29342418-1 2018 Cytochrome P450 2A13 (CYP2A13) is responsible for the metabolism of chemical compounds such as nicotine, coumarin, and tobacco-specific nitrosamine. Nicotine 95-103 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 22-29 29342418-5 2018 In this study, we performed an in vitro analysis of the wild-type enzyme (CYP2A13.1) and 8 CYP2A13 allelic variants, using nicotine and coumarin as representative CYP2A13 substrates. Nicotine 123-131 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 74-81 29342418-5 2018 In this study, we performed an in vitro analysis of the wild-type enzyme (CYP2A13.1) and 8 CYP2A13 allelic variants, using nicotine and coumarin as representative CYP2A13 substrates. Nicotine 123-131 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 91-98 29342418-5 2018 In this study, we performed an in vitro analysis of the wild-type enzyme (CYP2A13.1) and 8 CYP2A13 allelic variants, using nicotine and coumarin as representative CYP2A13 substrates. Nicotine 123-131 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 91-98 29342418-6 2018 These CYP2A13 variant proteins were heterologously expressed in 293FT cells, and the kinetic parameters of nicotine C-oxidation and coumarin 7-hydroxylation were estimated. Nicotine 107-115 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 6-13 28856944-1 2017 The human liver cytochrome P450 (CYP) 2A6 and the respiratory CYP2A13 enzymes play role in nicotine metabolism and activation of tobacco-specific nitrosamine carcinogens. Nicotine 91-99 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 62-69 23903410-1 2014 Human cytochrome P450 CYP2A6 and CYP2A13 catalyze nicotine metabolisms and mediate activation of tobacco-specific carcinogens including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Nicotine 50-58 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 33-40 25547627-9 2015 The feline CYP2A13 protein heterogeneously expressed in Escherichia coli showed metabolic activity similar to those of human and canine CYP2As for coumarin, 7-ethoxycoumarin and nicotine. Nicotine 178-186 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 11-18 23907605-7 2013 All the above effects were inhibited by nicotine (a substrate of CYP2A13) or 8-MOP (an inhibitor of CYP enzymes), confirming that CYP2A13 mediated the AFG1-induced cytotoxicity and DNA damages. Nicotine 40-48 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 65-72 23907605-7 2013 All the above effects were inhibited by nicotine (a substrate of CYP2A13) or 8-MOP (an inhibitor of CYP enzymes), confirming that CYP2A13 mediated the AFG1-induced cytotoxicity and DNA damages. Nicotine 40-48 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 130-137 23602888-11 2013 These effects could be almost completely inhibited by 100 muM nicotine (a substrate of CYP2A13) or 1 muM 8-methoxypsoralen (8-MOP; an inhibitor of CYP enzyme). Nicotine 62-70 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 87-94 22743290-9 2012 Finally, treatment with nicotine, a competitor of AFB(1), and 8-methoxypsoralen (8-MOP), an inhibitor of CYP enzyme, further confirm the critical role of CYP2A13 in AFB(1)-induced cytotoxicity and apoptosis. Nicotine 24-32 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 154-161 17428784-1 2007 The human lung cytochrome P450 2A13 (CYP2A13) activates the nicotine-derived procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) into DNA-altering compounds that cause lung cancer. Nicotine 60-68 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 15-35 19434638-2 2009 These compounds were tested as inhibitors of CYP2A6 and CYP2A13--two cytochrome P450 enzymes present in the respiratory tract--with a view to preventing the formation of carcinogenic metabolites of nicotine and inhibiting the metabolism of fragrances. Nicotine 198-206 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 56-63 22700965-3 2012 X-ray structures of nicotine complexes with CYP2A13 (2.5 A) and CYP2A6 (2.3 A) yield a structural rationale for the preferential binding of nicotine to CYP2A13. Nicotine 20-28 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 44-51 22700965-3 2012 X-ray structures of nicotine complexes with CYP2A13 (2.5 A) and CYP2A6 (2.3 A) yield a structural rationale for the preferential binding of nicotine to CYP2A13. Nicotine 20-28 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 152-159 22700965-3 2012 X-ray structures of nicotine complexes with CYP2A13 (2.5 A) and CYP2A6 (2.3 A) yield a structural rationale for the preferential binding of nicotine to CYP2A13. Nicotine 140-148 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 44-51 22700965-3 2012 X-ray structures of nicotine complexes with CYP2A13 (2.5 A) and CYP2A6 (2.3 A) yield a structural rationale for the preferential binding of nicotine to CYP2A13. Nicotine 140-148 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 152-159 22700965-7 2012 Altogether these structures provide multiple new snapshots of CYP2A13 conformations that assist in understanding the binding and activation of an important human carcinogen, as well as critical comparisons in the binding of nicotine, one of the most widely used and highly addictive drugs in human use. Nicotine 224-232 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 62-69 18779312-2 2008 A number of compounds, including nicotine, cotinine, and aflatoxin B(1), are metabolites of the 94% identical CYP2A13 and CYP2A6 enzymes but at different rates. Nicotine 33-41 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 110-117 17428784-1 2007 The human lung cytochrome P450 2A13 (CYP2A13) activates the nicotine-derived procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) into DNA-altering compounds that cause lung cancer. Nicotine 60-68 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 37-44 15528319-0 2005 Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Nicotine 14-22 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 45-65 17178771-1 2007 Human cytochrome CYP2A13 shows overlapping substrate specificity with CYP2A6, catalyzing the metabolism of coumarin, nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Nicotine 117-125 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 17-24 15528319-3 2005 Recently, we have demonstrated that heterologously expressed human CYP2A13 is highly active in the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a nicotine-derived carcinogen. Nicotine 169-177 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 67-74 15528319-4 2005 In the present study, CYP2A13-catalyzed NNK metabolism was found to be inhibited competitively by nicotine and N"-nitrosonornicotine (NNN), suggesting that both nicotine and NNN are also substrates of CYP2A13. Nicotine 98-106 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 22-29 15528319-4 2005 In the present study, CYP2A13-catalyzed NNK metabolism was found to be inhibited competitively by nicotine and N"-nitrosonornicotine (NNN), suggesting that both nicotine and NNN are also substrates of CYP2A13. Nicotine 98-106 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 201-208 15528319-4 2005 In the present study, CYP2A13-catalyzed NNK metabolism was found to be inhibited competitively by nicotine and N"-nitrosonornicotine (NNN), suggesting that both nicotine and NNN are also substrates of CYP2A13. Nicotine 124-132 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 22-29 15528319-4 2005 In the present study, CYP2A13-catalyzed NNK metabolism was found to be inhibited competitively by nicotine and N"-nitrosonornicotine (NNN), suggesting that both nicotine and NNN are also substrates of CYP2A13. Nicotine 124-132 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 201-208 15528319-5 2005 We have further demonstrated that human CYP2A13 is indeed an efficient enzyme in catalyzing C-oxidation of nicotine to form cotinine, with the apparent K(m) and V(max) values of 20.2 microM and 8.7 pmol/min/pmol, respectively. Nicotine 107-115 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 40-47 15528319-7 2005 The importance of CYP2A13-catalyzed nicotine and cotinine metabolism in vivo remains to be determined. Nicotine 36-44 cytochrome P450 family 2 subfamily A member 13 Homo sapiens 18-25